Tetracycline and epidermolysis bullosa simplex: a double-blind, placebo-controlled, crossover randomized clinical trial

The efficacy of trimethoprim in wound healing of patients with epidermolysis bullosa: A feasibility trial

“…8 The placebo-controlled crossover randomized trial of tetracycline in EBS failed to show statistical significance, but lesion counts in 4 of 6 patients showed a mean reduction of 59.5% (range of 40.6%-71.1%), indicating a trend toward improvement. 9 During the past 5 years, we have observed a substantial clinical improvement in the overall wound healing and decreased blister formation in more than 50 patients with different types of EB, followed up in the specialized EB clinic, treated with low-dose anti-inflammatory systemic antibiotics in alternating cycles of 2 to 3 months' duration. Our proof-of-concept study revealed improvement in the wound SA in all patients, with a trend toward greater improvement when patients were receiving TMP.…”

Progress towards genetic and pharmacological therapies for keratin genodermatoses: current perspective and future promise

“…Similar to doxycycline discussed earlier, there are anecdotal reports of successful treatment with another anti‐inflammatory agent, tetracycline , which may prevent tumor necrosis factor alpha release or modulate the activity of metalloproteinases, to reduce bulla formation. However, a randomized trial did not reveal any difference between antibiotic and placebo‐treated groups . Aminoglycosides family antimicrobials may lead to translation of proteins in individuals with premature termination codon mutations by transcript read through.…”

Localized Epidermolysis Bullosa Simplex (Weber-Cockayne type)

“…Topical aluminum chloride hexahydrate 20% and oral tetracycline 1.5 gm per day may also help reduce blisters. 14,15 Plantar injection of botulinum toxin has also been shown to reduce the number of blisters and pain associated with blistering. 16 Nutrition should be optimized to promote wound healing.…”